Viewing data from:

ERYTHROMYCIN ETHYLSUCCINATE

ANDA

ERYTHROMYCIN ETHYLSUCCINATE | A061904 | CARNEGIE PHARMACEUTICALS LLC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Erythromycin Ethylsuccinate (2023)

Total Spending

$4.5M

Total Claims

6,905

Beneficiaries

1,861

Avg Cost/Unit

$3.47

Spending Trend

$4.6M(2019)→$4.6M(2020)→$4.6M(2021)→$4.7M(2022)→$4.5M(2023)

YoY Change:-0.2%

5yr CAGR:+4.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain6 active DMFs9 inactive

6 active API suppliers hold Drug Master Files for this ingredient.

ABBVIE INCERYTHROMYCIN ETHYLSUCCINATE

DMF 134431998

ERCROS SAERYTHROMYCIN ETHYLSUCCINATE

DMF 136541998

ALEMBIC PHARMACEUTICALS LTDERYTHROMYCIN ETHYLSUCCINATE USP

DMF 314512017

SM BIOMED SDN BHDERYTHROMYCIN ETHYLSUCCINATE USP

DMF 317542017

CENTURY PHARMACEUTICALS LTDERYTHROMYCIN ETHYLSUCCINATE USP

DMF 345812020

SOLARA ACTIVE PHARMA SCIENCES LTDERYTHROMYCIN ETHYLSUCCINATE USP

DMF 350462020

ABBOTT LABORATORIES CHEMICAL AND AGRICULTURAL PRODUCTS DIVInactiveERYTHROMYCIN ETHYLSUCCINATE

DMF 132931998

ABBOTT LABORATORIES CHEMICAL AND AGRICULTURAL PRODUCTS DIVInactiveERYTHROMYCIN ETHYLSUCCINATE

DMF 135111998

ARCHIFAR LABInactiveERYTHROMYCIN ETHYLSUCCINATE

DMF 136001998

POLFAInactiveERYTHROMYCIN ETHYLSUCCINATE

DMF 135801998

DSM ANDENO GMBHInactiveERYTHROMYCIN ETHYLSUCCINATE

DMF 135811998

GIST-BROCADES NV PHARMACEUTICALSInactiveERYTHROMYCIN ETHYLSUCCINATE

DMF 135831998

COMPANHIA INDUSTRIAL PRODUTORA DE ANTIBIOTICOS SARLInactiveERYTHROMYCIN ETHYLSUCCINATE

DMF 135891998

FERMIC SA DE CVInactiveERYTHROMYCIN ETHYLSUCCINATE

DMF 137111998

SANDOZ INDUSTRIAL PRODUCTS SPAInactiveERYTHROMYCIN ETHYLSUCCINATE

DMF 157892001

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Feb 26, 2014	SUPPL -21	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 400MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.